{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T10:22:59Z","timestamp":1703758979702},"reference-count":45,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Aims To characterize the population pharmacokinetics of lamotrigine in\n                    Jordanian epileptic patients and to identify factors affecting therapeutic\n                    parameters.<\/jats:p><jats:p>\n          Patients and Methods A population pharmacokinetics model for lamotrigine\n                    was established based on a prospectively collected data of 52 steady-state\n                    concentrations from 38 adult and pediatric patients with epilepsy. Lamotrigine\n                    concentrations were determined by a dried blood spot liquid chromatography\n                    method. Data were analyzed according to a one-compartment model with first-order\n                    absorption and elimination using the nonlinear mixed effect modeling program.\n                    The covariates effect of total body weight, gender, age, and co-medication with\n                    topiramate, carbamazepine, phenytoin, phenobarbital, and valproic acid on\n                    lamotrigine clearance were investigated using a stepwise forward addition\n                    followed by a stepwise backward elimination.<\/jats:p><jats:p>\n          Results The final population pharmacokinetics model for lamotrigine\n                    clearance was as follows:\n                        CL\/Fpop=\u03b81*exp\n                        (\u03b83*age)*exp\n                        (\u03b85*carbamazepine)*exp\n                        (\u03b86*valproic acid) , where \u03b81\n                    is the relative clearance (L\/hr) estimated, and \u03b83,\n                        \u03b85, and \u03b86 are the fixed parameters\n                    relating to age and co-medication with carbamazepine and valproic acid,\n                    respectively.The population mean value of lamotrigine total clearance generated\n                    in the final model (with covariates) was 2.12\u2009L\/hr.\n                    Inter-individual variability and residual unexplained variability expressed as\n                    the coefficient of variation was 37.1 and 26.1%, respectively.<\/jats:p><jats:p>\n          Conclusion Lamotrigine total clearance in the Jordanian patients is\n                    comparable to that reported by others for Caucasian patients. Age and\n                    concomitant therapy with carbamazepine and valproic acid significantly affected\n                    lamotrigine clearance, and accounted for 48% of its inter-individual\n                    variability.<\/jats:p>","DOI":"10.1055\/a-1524-0913","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T14:04:51Z","timestamp":1626185091000},"page":"429-437","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics Modeling of Lamotrigine in Jordanian\n                    Epileptic Patients Using Dried Blood Spot Sampling"],"prefix":"10.1055","volume":"71","author":[{"given":"Yasmeen I.","family":"Dodin","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics and Clinical Pharmacy, Faculty of\n                    Pharmacy, The University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maysa F.","family":"Suyagh","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics and Clinical Pharmacy, Faculty of\n                    Pharmacy, The University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad I.","family":"Saleh","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics and Clinical Pharmacy, Faculty of\n                    Pharmacy, The University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad T.","family":"Nuseir","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Internal Medicine, Faculty of\n                    Medicine, The University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah M.","family":"Aburuz","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics and Clinical Pharmacy, Faculty of\n                    Pharmacy, The University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelkarim A.","family":"Al-Qudah","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Faculty of\n                    Medicine, The University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amira T.","family":"Masri","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Faculty of\n                    Medicine, The University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah M.","family":"Younes","sequence":"additional","affiliation":[{"name":"Private Neurology Clinic, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutasim A.","family":"Al-Ghazawi","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics and Clinical Pharmacy, Faculty of\n                    Pharmacy, The University of Jordan, Amman, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(98)00108-9","article-title":"Progress report on new antiepileptic drugs: A summary of the fourth Eilat\n                    conference (EILAT IV)","volume":"34","author":"M Bialer","year":"1999","journal-title":"Epilepsy Res"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.1996.tb00046.x","article-title":"The new generation of antiepileptic drugs: Advantages and disadvantages","volume":"42","author":"E Perucca","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0920-1211(98)00095-3","article-title":"Monotherapy trials with the new antiepileptic drugs: study designs, practical\n                    relevance and ethical implications","volume":"33","author":"E Perucca","year":"1999","journal-title":"Epilepsy Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0014-2999(96)00265-8","article-title":"Lamotrigine inhibits Ca2+currents in cortical neurons:\n                    Functional implications","volume":"307","author":"A Stefani","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":"The influence of dosage, age, and comedication on steady state plasma\n                    lamotrigine concentrations in epileptic children: A prospective study with\n                    preliminary assessment of correlations with clinical response","volume":"19","author":"A Bartoli","year":"1997","journal-title":"Ther Drug Monit"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","article-title":"Lamotrigine and therapeutic drug monitoring: retrospective survey following the\n                    introduction of a routine service","volume":"46","author":"R G Morris","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2165\/00003088-199325060-00003","article-title":"Lamotrigine clinical pharmacokinetics","volume":"25","author":"B Rambeck","year":"1993","journal-title":"Clin Pharmacokinetic"},{"key":"ref8"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1111\/j.1528-1157.1999.tb02088.x","article-title":"The clinical Pharmacokinetics of the new antiepileptic drugs","volume":"40","author":"E Perucca","year":"1999","journal-title":"Epilepsia."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00007691-199610000-00001","article-title":"Serum concentrations of lamotrigine in epileptic patients: the influence of dose\n                    and comedication","volume":"18","author":"T W May","year":"1996","journal-title":"Ther Drug Monit"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00007691-200106000-00006","article-title":"Single-dose pharmacokinetics of lamotrigine in children: influence of age and\n                    antiepileptic comedication","volume":"23","author":"D Battino","year":"2001","journal-title":"Ther Drug Monit"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","article-title":"Population pharmacokinetics of lamotrigine with data from therapeutic drug\n                    monitoring in German and Spanish patients with epilepsy","volume":"30","author":"N Rivas","year":"2008","journal-title":"Ther Drug Monit"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","article-title":"Population pharmacokinetics of lamotrigine","volume":"23","author":"V Chan","year":"2001","journal-title":"Ther Drug Monit"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5414\/CPP47752","article-title":"Population pharmacokinetics of lamotrigine in patients with epilepsy","volume":"47","author":"J R Milovanovic","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2710.2012.01351.x","article-title":"Impact of age, weight and concomitant treatment on lamotrigine\n                    pharmacokinetics","volume":"37","author":"B B Brzakovi\u0107","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00228-007-0308-2","article-title":"Lamotrigine in children and adolescents: the impact of age on its serum\n                    concentrations and on the extent of drug interactions","volume":"63","author":"A Reimers","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/aps.2012.118","article-title":"Population pharmacokinetics of lamotrigine in Chinese children with\n                    epilepsy","volume":"33","author":"D K He","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00228-016-2190-2","article-title":"Population pharmacokinetic models of lamotrigine in different age groups of\n                    Chinese children with epilepsy","volume":"73","author":"Z B Zhang","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00228-012-1311-9","article-title":"Population pharmacokinetics of lamotrigine in Indian epileptic patients","volume":"69","author":"S Mallaysamy","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","article-title":"Population pharmacokinetics of lamotrigine adjunctive therapy in adults with\n                    epilepsy","volume":"39","author":"T H Grasela","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with\n                    epilepsy: Retrospective analysis of routine monitoring data","volume":"43","author":"Z Hussein","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","article-title":"Population pharmacokinetics of lamotrigine in elderly patients","volume":"48","author":"B Punyawudho","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1365\/s10337-010-1569-y","article-title":"A simple dried blood spot assay for therapeutic drug monitoring of\n                    lamotrigine","volume":"71","author":"S AbuRuz","year":"2010","journal-title":"Chromatographia."},{"key":"ref25","volume-title":"NONMEM Users Guide: Part I-VII","author":"S L Beal"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cmpb.2005.02.003","article-title":"NONMEMory: a run management tool for NONMEM","volume":"78","author":"J J Wilkins","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose\u2013an S-PLUS based population pharmacokinetic\/pharmacodynamic\n                    model building aid for NONMEM","volume":"58","author":"E N Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1023\/a:1011970125687","article-title":"Automated covariate model building within NONMEM","volume":"15","author":"E N Jonsson","year":"1998","journal-title":"Pharm Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2000.00237.x","article-title":"Validation of a population pharmacokinetic model for adjunctive lamotrigine\n                    therapy in children","volume":"50","author":"C Chen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.xphs.2020.05.030","article-title":"Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in\n                    Mexican Adult Patients With Epilepsy","volume":"109","author":"C E Ch\u00e1vez-Castillo","year":"2020","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","article-title":"The influence of dosage, age and comedication on steady-state plasma lamotrigine\n                    concentrations in epileptic children: a prospective study with preliminary\n                    assessment of correlations with clinical response","volume":"19","author":"A Bartoli","year":"1997","journal-title":"Ther Drug Monit"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-199904000-00008","article-title":"Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant\n                    antiepileptic drugs and dosage implications","volume":"21","author":"J A Armijo","year":"1999","journal-title":"Ther Drug Monit"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1992.tb04079.x","article-title":"Sodium valproate acutely inhibits lamotrigine metabolism","volume":"33","author":"AW C Yuen","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-9236(96)90130-7","article-title":"Bidirectional interaction of valproate and lamotrigine in healthy subjects","volume":"60","author":"G D Anderson","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in\n                    epileptic patients with and without valproic acid comedication: Result of a\n                    retrospective study","volume":"21","author":"T W May","year":"1999","journal-title":"Ther Drug Monit"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":"Effect of antiepileptic drug comedication on lamotrigine clearance","volume":"62","author":"D Weintraub","year":"2005","journal-title":"Arch Neurol"},{"key":"ref37","first-page":"508","article-title":"Population Pharmacokinetics of add-on lamotrigine in pediatric patients","volume":"42","author":"C Chen","year":"1997","journal-title":"Ann Neurol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.19.6.437.31052","article-title":"Pharmacokinetics of lamotrigine in children in the absence of other\n                    antiepileptic drugs","volume":"19","author":"C Chen","year":"1999","journal-title":"Pharmacotherapy"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00007691-199908000-00094","article-title":"Topiramate decreases lamotrigine concentrations","volume":"21","author":"W Wnuk","year":"1999","journal-title":"Ther Drug Monit"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1528-1157.2002.37701.x","article-title":"Lack of an effect of topiramate on lamotrigine serum concentration","volume":"43","author":"D J Berry","year":"2002","journal-title":"Epilepsia"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1528-1157.2003.64402.x","article-title":"Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and\n                    combination therapy in epilepsy patients","volume":"44","author":"D R Doose","year":"2003","journal-title":"Epilepsia"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/j.1528-1167.2011.03217.x","article-title":"The effect of age and comedication on lamotrigine clearance, tolerability, and\n                    efficacy","volume":"52","author":"H Arif","year":"2011","journal-title":"Epilepsia"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00007691-199712000-00003","article-title":"Lamotrigine plasma concentrations in children and adults: influence of age and\n                    associated therapy","volume":"19","author":"D Battino","year":"1997","journal-title":"Ther Drug Monit"},{"key":"ref44","first-page":"19","article-title":"Comparison of lamotrigine pharmacokinetics in young and elderly healthy\n                    volunteers","volume":"18","author":"J Posner","year":"1991","journal-title":"J Pharmacol Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.4155\/bio.10.159","article-title":"Pharmacokinetic considerations as to when to use dried blood spot sampling","volume":"2","author":"G Emmons","year":"2010","journal-title":"Bioanalysis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1208\/s12248-009-9112-5","article-title":"Handling data below the limit of quantification in mixed effect models","volume":"11","author":"M Bergstrand","year":"2009","journal-title":"AAPS J"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1524-0913.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T01:04:07Z","timestamp":1632359047000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1524-0913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":45,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2021,9,22]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1524-0913","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]}}}